Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy
Purpose Clinicopathologic features and biochemical recurrence are sensitive, but not
specific, predictors of metastatic disease and lethal prostate cancer. We hypothesize that a …
specific, predictors of metastatic disease and lethal prostate cancer. We hypothesize that a …
Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy
AJ Stephenson, A Smith, MW Kattan… - … Journal of the …, 2005 - Wiley Online Library
BACKGROUND Gene expression profiling of prostate carcinoma offers an alternative means
to distinguish aggressive tumor biology and may improve the accuracy of outcome …
to distinguish aggressive tumor biology and may improve the accuracy of outcome …
Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population
RJ Karnes, EJ Bergstralh, E Davicioni… - The Journal of …, 2013 - auajournals.org
Purpose: Patients with locally advanced prostate cancer after radical prostatectomy are
candidates for secondary therapy. However, this higher risk population is heterogeneous …
candidates for secondary therapy. However, this higher risk population is heterogeneous …
Gene expression profiling predicts clinical outcome of prostate cancer
GV Glinsky, AB Glinskii, AJ Stephenson… - The Journal of …, 2004 - Am Soc Clin Investig
One of the major problems in management of prostate cancer is the lack of reliable genetic
markers predicting the clinical course of the disease. We analyzed expression profiles of …
markers predicting the clinical course of the disease. We analyzed expression profiles of …
A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy
Background: Due to their varied outcomes, men with biochemical recurrence (BCR)
following radical prostatectomy (RP) present a management dilemma. Here, we evaluate …
following radical prostatectomy (RP) present a management dilemma. Here, we evaluate …
[HTML][HTML] Expression signatures that correlated with Gleason score and relapse in prostate cancer
M Bibikova, E Chudin, A Arsanjani, L Zhou, EW Garcia… - Genomics, 2007 - Elsevier
Predicting prognosis in prostate carcinoma remains a challenge when using clinical and
pathologic criteria only. We used an array-based DASL® assay to identify molecular …
pathologic criteria only. We used an array-based DASL® assay to identify molecular …
Performance of a prostate cancer genomic classifier in predicting metastasis in men with prostate-specific antigen persistence postprostatectomy
DE Spratt, DLY Dai, RB Den, P Troncoso, K Yousefi… - European urology, 2018 - Elsevier
Background Prostate cancer patients who have a detectable prostate-specific antigen (PSA)
postprostatectomy may harbor pre-existing metastatic disease. To our knowledge, none of …
postprostatectomy may harbor pre-existing metastatic disease. To our knowledge, none of …
Defining aggressive prostate cancer using a 12-gene model
The critical clinical question in prostate cancer research is: How do we develop means of
distinguishing aggressive disease from indolent disease? Using a combination of proteomic …
distinguishing aggressive disease from indolent disease? Using a combination of proteomic …
A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical …
EA Klein, K Yousefi, Z Haddad, V Choeurng, C Buerki… - European urology, 2015 - Elsevier
Background Surgery is a standard first-line therapy for men with intermediate-or high-risk
prostate cancer. Clinical factors such as tumor grade, stage, and prostate-specific antigen …
prostate cancer. Clinical factors such as tumor grade, stage, and prostate-specific antigen …
Validation of a 22-gene genomic classifier in patients with recurrent prostate cancer: an ancillary study of the NRG/RTOG 9601 randomized clinical trial
Importance Decipher (Decipher Biosciences Inc) is a genomic classifier (GC) developed to
estimate the risk of distant metastasis (DM) after radical prostatectomy (RP) in patients with …
estimate the risk of distant metastasis (DM) after radical prostatectomy (RP) in patients with …
相关搜索
- genomic classifier radical prostatectomy
- prostate cancer expression signatures
- early metastasis radical prostatectomy
- early metastasis prostate cancer
- genomic classifier prostate cancer
- prostate cancer radical prostatectomy
- discovery and validation radical prostatectomy
- prostate cancer discovery and validation
- early metastasis discovery and validation
- genomic classifier biochemical recurrence
- genomic classifier metastatic disease
- clinical variables radical prostatectomy
- prostate cancer gleason score
- prostate cancer clinical outcome
- genomic classifier adjuvant therapy
- adjuvant therapy radical prostatectomy